EAACI Congress 2024
BackEosinophilic esophagitis
Sunday 02 Jun, 12:00 PM -
13:00 PM Valencia, Spain
Poster Zone
Thematic Poster Session
12:00
Characterization of patients with Eosinophilic Esophagitis and response to first-line treatment in a Portuguese Immunoallergology Department
12:00
Clinical and atopic features of patients with primary eosinophilic colitis: an Italian multicentre study
12:00
Dupilumab improves histologic, symptomatic, and endoscopic outcomes in children with eosinophilic esophagitis in the EoE KIDS study, regardless of history of elimination diet or concomitant food allergy
12:00
Dupilumab normalized the esophageal transcriptome in children aged 1 to <12 years with eosinophilic esophagitis (EoE) in the Phase 3 EoE KIDS trial
12:00
Eosinophilic Esophagitis and Neurodevelopmental Disorders: a potential association requiring further investigations
12:00
Eosinophilic Esophagitis in Children: Challenges and Solutions in Dietary Therapy
12:00
GPR15L induces chemotaxis of GPR15+ CD4 memory T cells and may facilitate their extravasation into the esophageal mucosa in Eosinophilic Esophagitis (EoE)
12:00
Half-Dose Response To Swallowed Topıcal Cortıcosteroıds In Chıldren Wıth Eosınophılıc Esophagıtıs
12:00
IL-4 impairs the esophageal epithelial barrier function in vitro more potently than IL-13
12:00
IgE-Mediated Food Allergies in Children with Eosinophilic Esophagitis
12:00
Tissue-specific inducible expression of IL-33 elicits features of eosinophilic esophagitis
